Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Compound Beclomethasone Camphor Cream is a topical fixed-dose combination therapy developed by Zhejiang Yanan Pharmaceutical. It primarily contains beclomethasone dipropionate, a potent synthetic glucocorticoid, and camphor, a naturally occurring compound with mild analgesic and antipruritic properties. The formulation is indicated for the treatment of inflammatory and pruritic skin conditions, including eczema, neurodermatitis, contact dermatitis, and pruritus. Beclomethasone dipropionate exerts anti-inflammatory and vasoconstrictive effects by acting as an agonist at the glucocorticoid receptor, while camphor provides a cooling sensation and local anesthetic effect to alleviate itching and discomfort. The product is approved for marketing in China.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on beclomethasone dipropionate + camphor.